Stock 6955 SHANDONG BOAN BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shandong Boan Biotechnology Co., Ltd.

Equities

6955

CNE100005RV4

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 12:01:52 25/06/2024 pm IST 		5-day change 1st Jan Change
9.19 HKD -0.97% Intraday chart for Shandong Boan Biotechnology Co., Ltd. -0.76% -40.71%
28/05 China Accepts Boan Biotechnology's Biologics License Application for Type 2 Diabetes Drug MT
27/05 Shandong Boan Biotechnology Co., Ltd. Announces Acceptance of BLA in China for Dulaglutide Injection CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 8,906 7,175 4,394 - -
Enterprise Value (EV) 1 8,974 7,379 4,887 5,032 5,075
P/E ratio -26.1 x -61.3 x -23.8 x -30.7 x -110 x
Yield - - - - -
Capitalization / Revenue 17.3 x 11.6 x 6.08 x 4.72 x 3.14 x
EV / Revenue 17.4 x 11.9 x 6.76 x 5.41 x 3.63 x
EV / EBITDA -36.6 x -156 x -66.8 x -786 x 45.8 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book 6.28 x 5.44 x 3.87 x 4.43 x 4.62 x
Nbr of stocks (in thousands) 5,09,278 5,09,278 5,09,278 - -
Reference price 2 17.49 14.09 8.627 8.627 8.627
Announcement Date 27/03/23 25/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 516 618.1 722.5 930.4 1,399
EBITDA 1 -245.5 -47.17 -73.16 -6.403 110.9
EBIT 1 -318.3 -129.9 -177.7 -119.4 -1.444
Operating Margin -61.7% -21.02% -24.59% -12.84% -0.1%
Earnings before Tax (EBT) - - - - -
Net income - - - - -
Net margin - - - - -
EPS 2 -0.6700 -0.2300 -0.3628 -0.2809 -0.0785
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share 2 - - - - -
Announcement Date 27/03/23 25/03/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt 1 68.2 204 494 639 681
Net Cash position 1 - - - - -
Leverage (Debt/EBITDA) -0.2779 x -4.326 x -6.751 x -99.72 x 6.144 x
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) -22.3% -8.72% -15.1% -13.5% -4.12%
ROA (Net income/ Total Assets) - - - - -
Assets - - - - -
Book Value Per Share 2 2.790 2.590 2.230 1.950 1.870
Cash Flow per Share - - - - -
Capex 1 122 104 215 110 110
Capex / Sales 23.61% 16.87% 29.78% 11.82% 7.86%
Announcement Date 27/03/23 25/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Shandong Boan Biotechnology Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.627 CNY
Average target price
10.44 CNY
Spread / Average Target
+21.02%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
SHANDONG BOAN BIOTECHNOLOGY CO., LTD. Stock Shandong Boan Biotechnology Co., Ltd.
-40.71% 605M
CSL LIMITED Stock CSL Limited
+2.46% 93.98B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.42% 37.69B
BIOGEN INC. Stock Biogen Inc.
-12.43% 32.99B
UCB Stock UCB
+75.98% 28.27B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-11.70% 16.17B
INCYTE CORPORATION Stock Incyte Corporation
+1.53% 14.33B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.82% 11.44B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+190.36% 10.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-54.07% 9.26B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 6955 Stock
  4. Financials Shandong Boan Biotechnology Co., Ltd.